Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2022 11:00 ET | Source: Genmab A/S

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Media Release Copenhagen, Denmark, June 6, 2022 Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line...
June 01, 2022 12:21 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...
May 26, 2022 17:00 ET | Source: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignanciesOral...
May 17, 2022 14:32 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The...
May 12, 2022 10:00 ET | Source: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress

Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient...
May 11, 2022 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2022

May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first...
April 19, 2022 06:29 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

Company Announcement Net sales of DARZALEX® in the first quarter of 2022 totaled USD 1,856 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. COPENHAGEN, Denmark;...
April 13, 2022 17:25 ET | Source: Genmab A/S

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial...
April 07, 2022 19:44 ET | Source: Genmab A/S

Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

Company Announcement COPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with...
March 29, 2022 14:34 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 29, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...